Muromonab-CD3
Showing 26 - 50 of >10,000
Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)
Recruiting
- Safety and Efficacy
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Sep 27, 2023
Leukemia, Stem Cell Transplantation Trial in Munich (FBTA05)
Withdrawn
- Leukemia
- Stem Cell Transplantation
-
Munich, Bavaria, Germany3. Medizinische Klinik, Klinikum rechts der Isar der TU München
Dec 5, 2022
Ovarian Cancer Trial (Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in
Not yet recruiting
- Ovarian Cancer
- Autologous genetically modified ADP-A2M4CD8 cells
- Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
- (no location specified)
Jan 31, 2023
Diffuse Large B-cell Lymphoma (DLBCL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)
Recruiting
- Diffuse Large B-cell Lymphoma (DLBCL)
- Odronextamab
- +5 more
-
Westbury, New YorkClinical Research Alliance Inc
Oct 13, 2023
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma (MZL)
- Odronextamab
- +2 more
-
Chiang Mai, ThailandChiang Mai University
Nov 20, 2023
DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +6 more
- Axicabtagene Ciloleucel
- +10 more
- (no location specified)
Jan 13, 2023
Follicular Lymphoma (FL) Trial in Noblesville (Odronextamab, Rituximab, Cyclophosphamide)
Recruiting
- Follicular Lymphoma (FL)
- Odronextamab
- +5 more
-
Noblesville, IndianaInvestigative Clinical Research of Indiana
Oct 18, 2023
Follicular Lymphoma (FL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)
Recruiting
- Follicular Lymphoma (FL)
- Odronextamab
- +6 more
-
Westbury, New YorkClinical Research Alliance Inc
Oct 13, 2023
Interleukins in Periodontal Disease Progression
Recruiting
- Periodontitis
- Gingivitis
- Flow Cytometric Detection of Regulatory T Cells and Cytokines analysis by ELISA
-
Assiut, Asyut, EgyptDepartment of oral medicine, Periodontology, Oral diagnosis and
Nov 16, 2023
Colorectal Cancer, Cancer of Pancreas, Pancreatic Tumor Trial in Detroit (FOLFOX6, EGFRBi armed ATC Infusions)
Completed
- Colorectal Cancer
- +7 more
- FOLFOX6
- EGFRBi armed ATC Infusions
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Mar 30, 2022
COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive Trial in Houston (biological, drug, procedure)
Active, not recruiting
- COL6A3 Positive
- +3 more
- Aldesleukin
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib,
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Acalabrutinib
- CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
-
Duarte, CaliforniaCity of Hope Comprehensive Cancer Center
Jun 16, 2022
Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,
Recruiting
- Recurrent Hodgkin Lymphoma
- +3 more
- Brentuximab Vedotin
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 4, 2022
B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)
Not yet recruiting
- B-cell Non-Hodgkins Lymphoma (B-NHL)
- (no location specified)
Jan 5, 2023
Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei
Recruiting
- Diffuse Large B Cell Lymphoma
- +4 more
- CD19-targeted chimeric antigen receptor T-cell
-
Kaohsiung, Taiwan
- +2 more
Oct 25, 2022
Non Small Cell Lung Cancer, Lung Cancer Trial in Bronx (drug, biological, radiation)
Recruiting
- Non Small Cell Lung Cancer
- Lung Cancer
- FLT3 Ligand (CDX-301)
- +2 more
-
Bronx, New YorkAlbert Einstein College of Medicine
Jul 18, 2022
Leukemia, Relapsed, Myeloid Trial in Netherlands, Switzerland (MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123
Recruiting
- Leukemia
- +3 more
- MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
-
Amsterdam, Netherlands
- +4 more
Jan 4, 2023
Healthy Adults Trial in Créteil (Solo 0.3 group, Solo 1 group, Solo 3 group)
Recruiting
- Healthy Adults
- Solo 0.3 group
- +5 more
-
Créteil, France
- +2 more
Sep 9, 2022
Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma Trial in Duarte (Chlorotoxin
Recruiting
- Recurrent Glioblastoma
- +3 more
- Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)
- Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 25, 2022
Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia Trial in
Terminated
- Philadelphia Chromosome Negative
- +2 more
- Blinatumomab
- +11 more
-
Houston, TexasM D Anderson Cancer Center
Nov 3, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Los
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +5 more
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- +3 more
-
Los Angeles, CaliforniaUSC/Norris Comprehensive Cancer Center
Jan 31, 2023
Systemic Lupus Erythematosus, Systemic Sclerosis Trial in Philadelphia (Depletion of CD3/CD19 in an autologous stem cell
Recruiting
- Systemic Lupus Erythematosus
- Systemic Sclerosis
- Depletion of CD3/CD19 in an autologous stem cell transplant
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
May 23, 2022
Metastatic Triple Negative Breast Cancer Trial in Dallas (PLD Chemotherapy, CDX-1140, CDX-301)
Recruiting
- Metastatic Triple Negative Breast Cancer
- PLD Chemotherapy
- +2 more
-
Dallas, TexasUT Southwestern Medical Center
Jun 23, 2022
B Acute Lymphoblastic Leukemia Trial (procedure, biological, drug, radiation)
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- Biospecimen Collection
- +19 more
- (no location specified)
Nov 8, 2023